Nature Communications (Mar 2020)
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
- Anniina Färkkilä,
- Doga C. Gulhan,
- Julia Casado,
- Connor A. Jacobson,
- Huy Nguyen,
- Bose Kochupurakkal,
- Zoltan Maliga,
- Clarence Yapp,
- Yu-An Chen,
- Denis Schapiro,
- Yinghui Zhou,
- Julie R. Graham,
- Bruce J. Dezube,
- Pamela Munster,
- Sandro Santagata,
- Elizabeth Garcia,
- Scott Rodig,
- Ana Lako,
- Dipanjan Chowdhury,
- Geoffrey I. Shapiro,
- Ursula A. Matulonis,
- Peter J. Park,
- Sampsa Hautaniemi,
- Peter K. Sorger,
- Elizabeth M. Swisher,
- Alan D. D’Andrea,
- Panagiotis A. Konstantinopoulos
Affiliations
- Anniina Färkkilä
- Dana-Farber Cancer Institute
- Doga C. Gulhan
- Harvard Medical School
- Julia Casado
- Research Program in Systems Oncology, University of Helsinki
- Connor A. Jacobson
- Laboratory of Systems Pharmacology, Harvard Medical School
- Huy Nguyen
- Dana-Farber Cancer Institute
- Bose Kochupurakkal
- Dana-Farber Cancer Institute
- Zoltan Maliga
- Laboratory of Systems Pharmacology, Harvard Medical School
- Clarence Yapp
- Laboratory of Systems Pharmacology, Harvard Medical School
- Yu-An Chen
- Laboratory of Systems Pharmacology, Harvard Medical School
- Denis Schapiro
- Laboratory of Systems Pharmacology, Harvard Medical School
- Yinghui Zhou
- TESARO: A GSK company
- Julie R. Graham
- TESARO: A GSK company
- Bruce J. Dezube
- TESARO: A GSK company
- Pamela Munster
- Helen Diller Family Comprehensive Cancer Center
- Sandro Santagata
- Brigham and Women’s Hospital, Laboratory for Systems Pharmacology
- Elizabeth Garcia
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- Scott Rodig
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- Ana Lako
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- Dipanjan Chowdhury
- Dana-Farber Cancer Institute
- Geoffrey I. Shapiro
- Dana-Farber Cancer Institute
- Ursula A. Matulonis
- Dana-Farber Cancer Institute
- Peter J. Park
- Department of Biomedical Informatics, Harvard Medical School
- Sampsa Hautaniemi
- Research Program in Systems Oncology, University of Helsinki
- Peter K. Sorger
- Laboratory of Systems Pharmacology, Harvard Medical School
- Elizabeth M. Swisher
- University of Washington
- Alan D. D’Andrea
- Dana-Farber Cancer Institute
- Panagiotis A. Konstantinopoulos
- Dana-Farber Cancer Institute
- DOI
- https://doi.org/10.1038/s41467-020-15315-8
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 13
Abstract
A Phase I/II trial previously revealed variable anti-tumor efficacy of the PARP inhibitor niraparib in combination with the PD-1 inhibitor pembrolizumab in platinum-resistant ovarian cancer patients. Here, the authors perform an integrated genomic and immunomics analysis of tumor samples from the same patients and find potential predictive biomarkers of response to such combination therapy.
